Indian Journal of Dermatology
CASE REPORT
Year
: 2011  |  Volume : 56  |  Issue : 1  |  Page : 87--91

Extrinsic apoptotic pathways: A new potential DQTargetDQ for more sufficient therapy in a case of cutaneous anaplastic large CD30+ ALK-T--cell lymphoma


Georgi Tchernev1, Jos Carlos Cardoso2, Lubomir Arseniev3, Hiroyuki Okamoto4 
1 Department of Dermatology, Venereology and Dermatologic Surgery, MVZ Kirchheim, Steingaustrasse 13, 73230 Kirchheim unter Teck, Germany
2 Dermatology Department, University Hospital of Coimbra, Praceta Mota Pinto, 3000 075 Coimbra, Portugal
3 Cytonet Hannover GmbH, Feodor-Lynen-Str. 21, 30625 Hannover, Germany
4 Department of Dermatology, Kansai Medical University, 10-15 Fumizono, Moriguchi, Osaka 570-8507, Japan

Correspondence Address:
Georgi Tchernev
Specialist in Dermatology and Venereology, Department of Dermatology, Venereology and Dermatologic Surgery, MVZ Kirchheim unter Teck/VOP, Steingaustrasse 13, 73230 Kirchheim unter Teck, Baden Wrttemberg
Germany

The primary cutaneous T-cell lymphomas (CTCL) represent a clonal T-lymphocyte proliferation infiltrating the skin. CD30+ T-cell lymphomas present clinically as nodules with a diameter between 1 and 15 cm, mostly in elderly patients. The role of the CD30 molecule in patients suffering from T-cell lymphomas is not completely clear yet. The signal transduction pathway which includes CD30 seems to play a key role in tumor progression. In certain forms of T-cellular lymphomas, the interaction between CD30/CD30-ligand is able to provoke apoptosis of the DQtumor lymphocytesDQ. The modern conceptions of the pathogenesis of T-cell lymphomas include disorders in the pathways involved in programmed cellular death and disregulation in the expression of certain of its regulatory molecules. We are presenting an unusual case of a female patient with a primary cutaneous form of CD30 + /ALK anaplastic large T-cell lymphoma. Upon the introduction of systemic PUVA, (psoralen plus ultraviolet light radiation) combined with beam therapy, a complete remission could be noticed. Eight months later, we observed a local recurrence, which was overcome by CHOP chemotherapy (Cyclophosphamide, Hydroxydaunorubicin (Doxorubicin), Vincristin (Oncovin®), Predniso(lo)n). Six months later, new cutaneous lesions had been noticed again. A new therapeutic hope for the patients with anaplastic large CTCL is actually based on the influence of the activity of the different apoptotic pathways. Death ligands, including tumor necrosis factor (TNF)-α, CD95L/FasL, and TRAIL, mediate also some important safeguard mechanisms against tumor growth in patients with CD30 + cutaneous anaplastic large T-cell lymphomas and critically contribute to lymphocyte homeostasis.


How to cite this article:
Tchernev G, Cardoso JC, Arseniev L, Okamoto H. Extrinsic apoptotic pathways: A new potential "Target" for more sufficient therapy in a case of cutaneous anaplastic large CD30+ ALK-T--cell lymphoma.Indian J Dermatol 2011;56:87-91


How to cite this URL:
Tchernev G, Cardoso JC, Arseniev L, Okamoto H. Extrinsic apoptotic pathways: A new potential "Target" for more sufficient therapy in a case of cutaneous anaplastic large CD30+ ALK-T--cell lymphoma. Indian J Dermatol [serial online] 2011 [cited 2022 Jul 7 ];56:87-91
Available from: https://www.e-ijd.org/article.asp?issn=0019-5154;year=2011;volume=56;issue=1;spage=87;epage=91;aulast=Tchernev;type=0